CDK9 and T-cell non-Hodgkin lymphoma: As anticipated, MCL-1 dependent T-cell lymphomas were highly sensitive to CDK9 antagonism with AZD4573 (Fig. 2D), culminating in PARP and caspase 3 cleavage within 6 h of treatment (Fig. 2E).